<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250716066512N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-10-05</date_registration>
      <primary_sponsor>Larestan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Spiritual Reminiscence on Death Anxiety in Hospitalized Cardiac Patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of spiritual reminiscence on death anxiety in patients hospitalized in intensive care units.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85153</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Participants were selected using convenience sampling and allocated to two intervention and control groups using a two-person permuted block randomization (block size = 2). The random sequence was generated with Excel and implemented using sealed, numbered envelopes to ensure allocation concealment. The researcher was blinded to the sequence until assignment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Death anxiety.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to routine care, patients will participate in a spiritual reminiscence program over three consecutive days, with each session lasting 30–45 minutes: Session 1 focuses on the meaning of life and relationships, exploring the patient’s past and present experiences, identifying sources of meaning and joy, and discussing relationships with others and received spiritual support; Session 2 addresses hopes, fears, concerns, and religious beliefs, identifying the most challenging life experiences, current hopes and concerns, spiritual and religious beliefs, and the patient’s perceptions of the end of life; Session 3 covers spiritual and religious practices and a review, including reviewing religious activities, the impact of spiritual beliefs on life, and summarizing and revisiting the content of previous sessions. Sessions will be conducted individually in a calm environment by the researcher, and if the patient wishes, a family member may also attend. Patients can ask questions and receive spiritual support throughout the sessions. Intervention 2: Control group: Patients will receive only the routine care provided in the cardiac intensive care unit and will not receive any additional psychological or spiritual interventions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data of study participants can be shared after de-identifying individuals, and only a portion of the data, such as information related to the main outcome, can be shared.

When:
Access begins 6 months after results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
The use of the data or documents is limited to scientific analyses, writing research articles, or performing statistical evaluations related to the study objectives. Any use outside this scope, including the disclosure of identifiable information or transfer of data to third parties, is prohibited.

Where to obtain:
jaymandzahra261@gmail.com

How to obtain:
After sending a request message to the author's email and stating the reasons, the requester can access the data files in a short period of time (less than 20 days).

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>MohammadRafi BazrAfshan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Larestan University of Medical Sciences, Velayat Boulevard, Imam Khomeini Square</address>
        <city>Larestan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7418945519</zip>
        <telephone>+98 71 5423 1027</telephone>
        <email>m.rafibazrafshan@gmail.com</email>
        <affiliation>Larestan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>MohammadRafi BazrAfshan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Larestan University of Medical Sciences, Velayat Boulevard, Imam Khomeini Square</address>
        <city>Larestan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7418945519</zip>
        <telephone>+98 71 5423 1027</telephone>
        <email>m.rafibazrafshan@gmail.com</email>
        <affiliation>Larestan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Confirmed diagnosis of heart disease by the attending physician
Hospitalization in the cardiac intensive care unit
Full consciousness and ability to communicate verbally
Willingness and informed consent to participate in the study</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Death of a first-degree relative within the past 6 months
Severe psychiatric disorders (major depression, schizophrenia, bipolar disorder)
Use of psychiatric drugs affecting mood or anxiety
Addiction to alcohol or illicit drugs
Intellectual disability, blindness, deafness, or moderate to severe cognitive impairment
Participation in similar interventions within the past 6 months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F06.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anxiety disorder due to known physiological condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to routine care, patients will participate in a spiritual reminiscence program over three consecutive days, with each session lasting 30–45 minutes: Session 1 focuses on the meaning of life and relationships, exploring the patient’s past and present experiences, identifying sources of meaning and joy, and discussing relationships with others and received spiritual support; Session 2 addresses hopes, fears, concerns, and religious beliefs, identifying the most challenging life experiences, current hopes and concerns, spiritual and religious beliefs, and the patient’s perceptions of the end of life; Session 3 covers spiritual and religious practices and a review, including reviewing religious activities, the impact of spiritual beliefs on life, and summarizing and revisiting the content of previous sessions. Sessions will be conducted individually in a calm environment by the researcher, and if the patient wishes, a family member may also attend. Patients can ask questions and receive spiritual support throughout the sessions.</i_keyword>
      <i_keyword>Control group: Patients will receive only the routine care provided in the cardiac intensive care unit and will not receive any additional psychological or spiritual interventions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>“Death anxiety score on the Templer Death Anxiety Scale. Timepoint: Before the initiation of the spiritual reminiscence intervention and immediately after its completion. Method of measurement: The Templer Death Anxiety Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>. Timepoint: . Method of measurement: .</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Larestan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-06-24</approval_date>
        <contact_name>Ethics Committee of Larestan Faculty of Medical Sciences</contact_name>
        <contact_address>Management of Research and Technology, Larestan University of Medical Sciences, Velayat Boulevard, Imam Khomeini Square Larestan Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
